Standardised versus individualised multiherb Chinese herbal medicine for oligomenorrhoea and amenorrhoea in polycystic ovary syndrome: a randomised feasibility and pilot study in the UK - PubMed (original) (raw)

Randomized Controlled Trial

Standardised versus individualised multiherb Chinese herbal medicine for oligomenorrhoea and amenorrhoea in polycystic ovary syndrome: a randomised feasibility and pilot study in the UK

Lily Lai et al. BMJ Open. 2017.

Abstract

Objectives: To explore feasibility of a randomised study using standardised or individualised multiherb Chinese herbal medicine (CHM) for oligomenorrhoea and amenorrhoea in women with polycystic ovary syndrome (PCOS), to pilot study methods and to obtain clinical data to support sample size calculations.

Design: Prospective, pragmatic, randomised feasibility and pilot study with participant and practitioner blinding.

Setting: 2 private herbal practices in the UK.

Participants: 40 women diagnosed with PCOS and oligomenorrhoea or amenorrhoea following Rotterdam criteria.

Intervention: 6 months of either standardised CHM or individualised CHM, 16 g daily taken orally as a tea.

Main outcome measures: Our primary objective was to determine whether oligomenorrhoea and amenorrhoea were appropriate as the primary outcome measures for the main study. Estimates of treatment effects were obtained for menstrual rate, body mass index (BMI), weight and hirsutism. Data were collected regarding safety, feasibility and acceptability.

Results: Of the 40 participants recruited, 29 (72.5%) completed the study. The most frequently cited symptoms of concern were hirsutism, weight and menstrual irregularity. Statistically significant improvements in menstrual rates were found at 6 months within group for both standardised CHM (mean difference (MD) 0.18±0.06, 95% CI 0.06 to 0.29; p=0.0027) and individualised CHM (MD 0.27±0.06, 95% CI 0.15 to 0.39; p<0.001), though not between group (p=0.26). No improvements were observed for BMI nor for weight in either group. Improvements in hirsutism scores found within group for both groups were not statistically significant between group (p=0.09). Liver and kidney function and adverse events data were largely normal. Participant feedback suggests changing to tablet administration could facilitate adherence.

Conclusions: A CHM randomised controlled trial for PCOS is feasible and preliminary data suggest that both individualised and standardised multiherb CHMs have similar safety profiles and clinical effects on promoting menstrual regularity. These data will inform the design of a study in primary care that will incorporate an appropriate control.

Trial registration number: ISRCTN 31072075; Results.

Keywords: COMPLEMENTARY MEDICINE; Chinese herbal medicine; PRIMARY CARE; Polycystic Ovary Syndrome; Traditional Chinese Medicine.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1

CONSORT participant flow chart. ALT, alanine aminotransferase.

Cited by

Effectiveness of Zhenqi Buxue Oral Liquid Combined with Progesterone for Treatment of Oligomenorrhea and Hypomenorrhea with Qi-Blood and Kidney (Shen) Essence Deficiency: A Randomized Controlled Trial.
Gan JW, Lv DX, Fu J, Shi LY, Yuan CY, Zeng XQ, Li J, Sun AJ. Gan JW, et al. Chin J Integr Med. 2023 Nov;29(11):963-970. doi: 10.1007/s11655-023-3740-y. Epub 2023 Aug 18. Chin J Integr Med. 2023. PMID: 37594704 Clinical Trial.
Effects of TCM on polycystic ovary syndrome and its cellular endocrine mechanism.
Chen H, Deng C, Meng Z, Meng S. Chen H, et al. Front Endocrinol (Lausanne). 2023 May 16;14:956772. doi: 10.3389/fendo.2023.956772. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37260441 Free PMC article. Review.
The mechanism of Leonuri Herba in improving polycystic ovary syndrome was analyzed based on network pharmacology and molecular docking.
Wu M, Liu H, Zhang J, Dai F, Gong Y, Cheng Y. Wu M, et al. J Pharm Pharm Sci. 2023 Feb 15;26:11234. doi: 10.3389/jpps.2023.11234. eCollection 2023. J Pharm Pharm Sci. 2023. PMID: 36942296 Free PMC article.
Effects of Bu Shen Hua Zhuo formula on the LPS/TLR4 pathway and gut microbiota in rats with letrozole-induced polycystic ovary syndrome.
Wang Y, Xiao H, Liu Y, Tong Q, Yu Y, Qi B, Bu X, Pan T, Xing Y. Wang Y, et al. Front Endocrinol (Lausanne). 2022 Aug 9;13:891297. doi: 10.3389/fendo.2022.891297. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36017323 Free PMC article.
A Reasonable Evaluation of Chuanxiong Rhizoma Processing with Wine through Comparative Pharmacokinetic Study of Bioactive Components: Dominant Effect on Middle Cerebral Artery Occlusion Model Rats.
Pei K, Cao L, Cao G, Cai H, Ning Y, Zhao T, Sun L, Liu H, Zhang S. Pei K, et al. J Anal Methods Chem. 2022 Mar 14;2022:8252038. doi: 10.1155/2022/8252038. eCollection 2022. J Anal Methods Chem. 2022. PMID: 35321518 Free PMC article.

References

1. Asunción M, Calvo RM, San Millán JL et al. . A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000;85:2434–8. 10.1210/jcem.85.7.6682 - DOI - PubMed
1. March WA, Moore VM, Willson KJ et al. . The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 2010;25:544–51. 10.1093/humrep/dep399 - DOI - PubMed
1. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005;352:1223–36. 10.1056/NEJMra041536 - DOI - PubMed
1. Balen AH, Conway GS, Kaltsas G et al. . Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod 1995;10:2107–11. - PubMed
1. Vutyavanich T, Khaniyao V, Wongtra-Ngan S et al. . Clinical, endocrine and ultrasonographic features of polycystic ovary syndrome in Thai women. J Obstet Gynaecol Res 2007;33:677–80. 10.1111/j.1447-0756.2007.00631.x - DOI - PubMed

Standardised versus individualised multiherb Chinese herbal medicine for oligomenorrhoea and amenorrhoea in polycystic ovary syndrome: a randomised feasibility and pilot study in the UK - PubMed (original) (raw)